Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.50 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3093197 | 0.86 | HTT (0.52) | ALDH1A1CYP19A1PKMLMNAMAPT | |
| SCHEMBL3091468 | 0.84 | MMP1 (0.49) | ALDH1A1MEP1BPKMLMNAMAPT | |
| SCHEMBL3082870 | 0.83 | MEP1B (0.47) | ALDH1A1MEP1BCYP19A1TDP1PKM | |
| SCHEMBL3088605 | 0.83 | CYP3A4 (0.48) | ALDH1A1POLBMEP1BCYP19A1TDP1 | |
| SCHEMBL3079705 | 0.81 | CYP19A1 (0.51) | ALDH1A1POLBCYP19A1LMNASMN1; SMN2 | |
| SCHEMBL3083887 | 0.74 | MMP2 (0.51) | LMNA | |
| SCHEMBL3085273 | 0.73 | ALDH1A1 (0.55) | ALDH1A1POLBMEP1BCYP19A1TDP1 | |
| SCHEMBL3087754 | 0.72 | MMP2 (0.52) | LMNA | |
| SCHEMBL3087707 | 0.70 | MMP2 (0.47) | ALDH1A1POLB | |
| SCHEMBL3091205 | 0.70 | ALDH1A1 (0.59) | ALDH1A1POLBMEP1BCYP19A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100234378-A1 | ALKYLSULFONAMIDE-SUBSTITUTED TRIAZOLES AS MATRIX METALLOPROTEASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2010-09-16 | — | — | US | claimed |
| US-20100234378-A1 | ALKYLSULFONAMIDE-SUBSTITUTED TRIAZOLES AS MATRIX METALLOPROTEASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2010-09-16 | — | — | US | disclosed |
| US-20100234378-A1 | ALKYLSULFONAMIDE-SUBSTITUTED TRIAZOLES AS MATRIX METALLOPROTEASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2010-09-16 | — | — | US | disclosed |
| US-20100234378-A1 | ALKYLSULFONAMIDE-SUBSTITUTED TRIAZOLES AS MATRIX METALLOPROTEASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2010-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234378-A1 | ALKYLSULFONAMIDE-SUBSTITUTED TRIAZOLES AS MATRIX METALLOPROTEASE INHIBITORS | MMP3, MMP11, MMP13 | ALDH1A1 1417/4885POLB 1633/4885MEP1B 759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.